2607-06-9 Usage
Originator
Nerisone,Schering,UK,1976
Uses
Different sources of media describe the Uses of 2607-06-9 differently. You can refer to the following data:
1. Glucocorticoid.
.
2. Difluocortolone is used as a topical therapy in the treatment of pediatric tinea corporis; a common mycotic infection in children.
Manufacturing Process
16α-Methyl-6α,9α-difluoro-δ4-pregnene-11α,21-diol-3,20-dione-21-acetate
(MP = 229°/232°-234°C (with decomposition) is dehydrogenated in 1.2-
position by means of Bacillus lentus, Mutant MB 284, whereby the 21-acetate
group is simultaneously saponified. (It is possible under the same conditions
to start with the free 21-hydroxyl compound.)For this purpose a fermenter made of stainless steel having a 50 liter capacity
is charged with 30 liters of a nutrient solution of 0.1% yeast extract, 0.5%
cornsteep and 0.2% glucose, heated for one-half hour at 120°C for
sterilization purposes, and after cooling, inoculated with a bacterial suspension
of Bacillus lentus MB 284.After 24 hours of growth at 28°C under stirring (220 revolutions per minute)
and aeration (1.65 m3/hr), 1.8 liters of the obtained culture is removed under
sterile conditions and transferred with 28 liters of the same sterilized nutrient
medium into a fermenter of the same size.Simultaneously, 6 g of 16α-methyl-6α,9α-difluoro-δ4-pregnene-11β,21-diol3,20-dione-21-acetate in 200 cc of dimethylformamide are added and the
fermentation is continued for 50 hours under the same conditions.The course of the fermentation is tested by removal of samples which are
extracted with methyl isobutyl ketone. The extracts are analyzed by thin layer
chromatography using a system of benzene/ethyl acetate (4:1).After further working up there is obtained an oily crystalline residue which is
subjected to chromatography on silica gel. The 16α-methyl-6α,9α-difluoroδ1,4-pregnadien-11β,21-diol-3,20-dione is eluated with ethyl acetatechloroform (1:2), it is recrystallized from ethyl acetate/ether and then formed
to melt at 240°/242°-244°C. The yield is 60% of the theoretical. The product
is reacted with valeric acid chloride to give the valerate ester.
Therapeutic Function
Antiinflammatory
Check Digit Verification of cas no
The CAS Registry Mumber 2607-06-9 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 2,6,0 and 7 respectively; the second part has 2 digits, 0 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 2607-06:
(6*2)+(5*6)+(4*0)+(3*7)+(2*0)+(1*6)=69
69 % 10 = 9
So 2607-06-9 is a valid CAS Registry Number.
InChI:InChI=1/C22H28F2O4/c1-11-6-13-14-8-16(23)15-7-12(26)4-5-21(15,3)22(14,24)18(28)9-20(13,2)19(11)17(27)10-25/h4-5,7,11,13-14,16,18-19,25,28H,6,8-10H2,1-3H3/t11-,13+,14+,16+,18+,19-,20+,21+,22+/m1/s1
2607-06-9Relevant articles and documents
Macrolactonolides: A novel class of anti-inflammatory compounds
Toma?kovi?, Linda,Komac, Marijana,Makaruha Stegi?, Oresta,Muni?, Vesna,Rali?, Jovica,Stani?, Barbara,Banjanac, Mihailo,Markovi?, Stribor,Hrva?i?, Bo?ka,?ip?i? Paljetak, Hana,Padovan, Jasna,Glojnari?, Ines,Erakovi? Haber, Vesna,Mesi?, Milan,Mer?ep, Mladen
, p. 321 - 332 (2013/02/23)
A new concept in design of safe glucocorticoid therapy was introduced by conjugating potent glucocorticoid steroids with macrolides (macrolactonolides). These compounds were synthesized from various steroid 17β-carboxylic acids and 9a-N-(3-aminoalkyl) derivatives of 9-deokso-9a-aza-9a-homoeritromicin A and 3-descladinosyl-9-deokso-9a-aza-9a-homoeritromicin A using stable alkyl chain. Combining property of macrolides to preferentially accumulate in immune cells, especially in phagocyte cells, with anti-inflammatory activity of classic steroids, we designed molecules which showed good anti-inflammatory activity in ovalbumin (OVA) induced asthma in rats. The synthesis, in vitro and in vivo anti-inflammatory activity of this novel class of compounds are described.
Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
-
, (2008/06/13)
Methods for reducing or preventing transplant rejection in the eye of an individual are described, comprising: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.